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A potent glucose-platinum conjugate exploits glucose trans-porters 
and preferentially accumulates in cancer cells 
Malay Patra,[a] Timothy C. Johnstone, [a] Kogularamanan Suntharalingam,[b] and Stephen J. Lippard*,[a] 
 
Abstract: Three rationally designed glucose-platinum 
conjugates (Glc-Pts) were synthesized and their biological 
activities evaluated. The Glc-Pts, 1-3, exhibit high levels of 
cytotoxicity toward a panel of cancer cells. The subcellular 
target and cellular uptake mechanism of the Glc-Pts were 
elucidated. For uptake into cells, Glc-Pt 1 exploits both glucose 
and organic cation transporters, both widely overexpressed in 
cancer. Compound 1 preferentially accumulates in and 
annihilates cancer, compared to normal epithelial, cells in vitro. 
Platinum-based anticancer drugs are among the most 
widely used of all chemotherapeutic treatments. Three 
FDA-approved platinum anticancer drugs, cisplatin, 
carboplatin, and oxaliplatin, have been in the clinic for 
many years to treat a variety of cancers including 
testicular, ovarian, cervical, head and neck, non-small-
cell lung, and colorectal.[1] Despite their success, 
platinum compounds have a number of deficiencies 
originating from a lack of tumor selectivity. Only a small 
fraction of the total administered platinum accumulates 
at the tumor site, resulting in sub-optimal drug 
concentration at the target. Moreover, accumulation of 
platinum in healthy tissue leads to undesired side effects 
including nephrotoxicity, myelosuppression, peripheral 
neuropathy, ototoxicity, and nausea.[1b, 2] These 
drawbacks need to be addressed when designing next 
generation platinum drugs. Novel strategies for 
introducing tumor-targeting properties into platinum 
anticancer drug candidates are therefore of great 
interest.[3]  
In order to maintain cellular homeostasis, growth, 
and proliferation, cancer cells significantly increase 
glucose uptake and the flux of metabolites through 
glycolysis. This phenomenon, termed “the Warburg 
effect,” arises from mitochondrial metabolic changes 
and is one of the hallmarks of cancer.[4] GLUT1, the most 
common glucose transporter, is widely overexpressed in 
many human cancers including hepatic, pancreatic, 
breast, esophageal, brain, renal, lung, cutaneous, 
colorectal, endometrial, ovarian, and cervical.[5] High 
GLUT1 expression levels in tumor biopsy samples 
correlate strongly with poor prognosis. Moreover, 
several other glucose transporters including GLUT2, 
GLUT3, GLUT12 and SGLT1/2 are also overexpressed 
in certain types of cancer cells.[5-6] Therefore 
glycoconjugation becomes an appealing strategy for 
targeted delivery of anticancer drugs. The potential of 
this strategy in diagnosis and therapy has already been 
realized, but there is much room for improvement.[7]  
Examples of glucose-platinum conjugates (Glc-Pts) in 
which the key structural features of the sugar unit are 
not perturbed, a prerequisite for optimal transporter 
recognition, and in which the sugar is linked to the 
platinum complex via a spacer are scarce.[8] Moreover, 
these previous studies fail to answer a crucial question 
in glycoconjugate development, are the conjugates 
actually taken up by the glucose transporters broadly 
expressed in cancer cells? 
 
Figure 1. (a) Structures of Glc-Pts 1-3 and their 
aglycone 4. (b) The hydrogen-bonding interactions 
present in the docking model of 1 into XylE (PDB 
4GBZ).[9] The protein is shown as grey ribbons with the 
sidechains of key residues depicted as sticks. Complex 
1 is shown as sticks and polar hydrogen atoms are 
explicitly portrayed. Hydrogen-bonding interactions are 
illustrated with dashed lines (See Figure S23 for the 
colored version of the docking model). 
In the present work, we report the synthesis, 
cytotoxicity, and detailed characterization of the cellular 
uptake mechanism of three novel Glc-Pts 1–3 (Figure 
1a). The design of these conjugates was guided by a 
recently published crystal structure of the bacterial 
xylose transporter XylE, a GLUT1 homolog.[9] Although 
a crystal structure of human GLUT1 has also recently 
been published,[10] in this latter study the protein was 
captured in the inward open configuration, as opposed 
to the outward open configuration that a platinum-
glucose conjugate would encounter when attempting to 
enter the cell. The XylE structure with bound D-glucose, 
on the other hand, exhibits the protein in an outward-
facing conformation. This structure reveals that all of the 
hydroxyl groups of D-glucose except that on C6 are 
involved in hydrogen-bonding interactions with various 
amino acid residues of the transporter. We hypothesized 
that modification at the C6 position of D-glucose should 
not, therefore, interfere with receptor binding. Previous 
reports have also suggested that the C6 position of D-
glucose can tolerate various functional groups while 
retaining substrate specificity for, and internalization by, 
GLUT1.[11] In fact, C6-glucose conjugates of 4-
nitrobenzofurazan, ketoprofen, and indomethacin were 
reported to bind GLUT1 with even higher affinity than 
unmodified D-glucose.[11a, 11c, 12] This property is highly 
desirable for a glucose-drug/fluorophore conjugate, 
which has to compete with the high level of glucose (~ 6 
mM) in the blood.[13]  
Initial docking studies using a DFT-optimized 
structure of the C6-glucose-platinum derivative 1 (Figure 
1b and S17) suggested that this complex is capable of 
binding in the cavity of an outward open XylE. The 
orientation of the sugar moiety in the docked complex 
differs from that of the glucose unit bound in the crystal 
structure, but hydrogen-bonding interactions occur with 
Gln168, Gln288, Tyr298, and Gln175. These residues 
had all been identified as key glucose-binding units in 
the XylE structure and either interact directly with the 
bound D-glucose or indirectly via hydrogen-bonded 
water molecules.[9] Additionally, Thr28 is capable of 
interacting with the carboxylate ligand of the platinum 
moiety.  
 
 
 
The synthesis of a C6-Glc-Pt compound has not, to our 
knowledge, been previously reported. We therefore had to 
establish feasible routes to Glc-Pts 1-3 (Scheme 1 and see 
SI for details). All new compounds were unambiguously 
characterized by NMR (1H, 13C, 195Pt) spectroscopy and 
electrospray ionization (ESI) mass spectrometry. The purity 
of the platinum complexes (1–4) was confirmed to be ≥95% 
by elemental microanalyses and analytical HPLC (Figure 
S1–S4).  
 
Scheme 1. Synthetic route for glucose-platinum conjugate 
 
The stability of this class of compounds in water and 
biological media was evaluated using compound 1. The rate 
of activation of platinum drugs by dissociation of the leaving 
group ligand(s) from the platinum center in the presence of 
biological nucleophiles follows the order dichloride 
(cisplatin) > oxalate (oxaliplatin) > malonate (carboplatin), 
suggesting high stability for Glc-Pt 1 because its leaving 
group ligand is similar to that of carboplatin.[14] Indeed we 
observed that 1 is highly stable in water as evidenced by no 
change in the 1H NMR spectrum of 1 after 72 h in D2O 
(Figure S18). In RPMI medium, which is used routinely for 
mammalian tissue culture, slow activation of 1 by the 
nucleophiles present in the medium was observed (Figure 
S19). This result is consistent with the previously reported 
activation of structurally similar platinum compounds by 
nucleophiles.[14a, 14b] No significant decomposition was 
noticed up to 8 h, and approximately 60% of 1 remained 
unchanged even after 24 h, suggesting that the compound 
is highly stable in biological media. As expected, the 
formation of 5 as a result of activation of 1 was confirmed 
by ESI-mass spectrometry (Figure S20). 
Cellular uptake studies in A2780, DU145 and A549 cells 
revealed that, of the three Glc-Pts, 1 is taken up most 
efficiently (Figure S5). We also observed a consistent 
decrease in uptake with increasing length of the linker 
joining the glucose and platinum moieties. It has been 
proposed that, upon binding to substrate in its outward open 
conformation, the GLUT1 transporter undergoes a 
conformational change in which the extracellular entrance 
to the cavity is occluded and an opening to the cytoplasmic 
side of the membrane forms, allowing the substrate to enter 
into the cell.[15] Steric hindrance caused by an overly long 
substrate could block this conformational change, and we 
propose that this phenomenon is responsible for our 
observation that glucose-platinum conjugates with longer 
linkers display reduced cellular uptake. In this respect, we 
note that when the structure of GLUT1 in the inward open 
form is aligned with that of XylE in the outward open form 
into which the Glc-Pts have been docked, significant steric 
clashes are observed for 3 but not 1 (Figure S17).[9-10] 
We next evaluated the cytotoxicity of 1–3 and their 
aglycone 4 against a panel of human cancer cells of 
different origin using the MTT (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide) assay, a standard assay 
for cytotoxicity evaluation. The IC50 (concentration required 
to reduce 50% cell viability) values derived from dose-
response curves are summarized in Table S1. The 
cytotoxicity of the Glc-Pt compounds is generally 
comparable to those of aglycone 4, but greater than that of 
cisplatin. Ovarian cancer A2780 cells were the most 
sensitive to the Glc-Pt compounds (IC50 = 0.15–0.22 µM). 
The relatively tight distribution of IC50 values for 1–3 
suggests that, whereas the length of the spacer between 
the glucose and platinum moieties significantly influences 
their cellular uptake, it is not the primary determinant of the 
IC50 values of these compounds.  
Although the previously described cellular uptake and 
cytotoxicity data may appear inconsistent, it is important to 
note that, for technical reasons, these initial assays were 
performed on different time scales. We subsequently 
investigated the effect of incubation time on the outcomes 
of these assays. Whereas the Glc-Pts were designed to be 
taken up by facilitated diffusion, the passive diffusion of the 
aglycone 4 will be impacted significantly by its lipophilicity 
and consequent ability to traverse the cellular membrane. 
We found that, even though the lipophilicity of 4 is 
approximately one log P unit higher than that of 1 (Figure 
S10a), the accumulation of 1 was significantly higher than 
that of 4 when cells were incubated with either compound 
for 8 h (Figure S11). This result highlights the importance of 
the glucose moiety of 1 in its cellular uptake. In contrast to 
the comparable activity of 1 and 4 observed in the 72 h 
incubation MTT assay (Table S1 and Figure S13b), an 8 h 
incubation MTT assay revealed 1 to be more cytotoxic than 
4 in both A2780 and DU145 cells (Figure S12, S13a & 
S13b), which is again consistent with the observed cellular 
uptake differences between 1 and 4 in an 8 h assay (Figure 
S11). We propose that the initial rate of accumulation of 1 
in cells is faster than that of 4, but that this protein-mediated 
transport becomes saturated at longer time scales. On the 
other hand, the passive uptake of 4 is slower but does not 
saturate. As a result, prolonged incubation with 4 allows the 
levels of cellular platinum accumulation and cytotoxcitity to 
approach that of 1. The difference in the cellular uptake 
between 1 and 4 diminishes with increased incubation time, 
monitored from 8 h to 17 h (Figure S13c).  
In order to obtain insight into possible subcellular targets 
of the Glc-Pts, we studied the intracellular distribution of 1 
and 2 as representatives of this class of compound in A2780 
cells. As shown in Figure S6, detection of platinum in the 
nucleus points to nuclear DNA as one potential target.[1a] 
Analysis of DNA platination levels (Figure S7a) revealed 
that 1 and 2 platinate nuclear DNA, the extent of which is 
764 ± 57 Pt adducts/10 
 
nucleotides for 1, 483 ± 79 Pt adducts/104 nucleotides 
for 2, and 685 ±17 adducts/104 nucleotides for oxaliplatin, 
which was included as a positive control. Increases in the 
expression levels of γH2AX, phos-p53, and phos-CHK2, 
which are canonical DNA damage biomarkers,[16] were also 
observed when cells were treated with increasing 
concentrations of 1 or 2 (Figure S7b). As expected for DNA-
targeting platinum compounds,[1a] cell cycle arrest at G2/M 
phase and induction of apoptosis were observed when 
A2780 cells were treated with compounds 1 or 2 and then 
analyzed by flow cytometry (Figure S8 & S9). Taken 
together, these results are consistent with the proposal that 
Glc-Pts target genomic DNA, the platination of which leads 
to apoptosis. 
As described earlier, one crucial question in 
glycoconjugate chemistry is whether or not the sugar-
conjugated molecule is actually transported by the targeted 
sugar transporters. To address this issue, we carried out a 
series of experiments to investigate the details of the 
mechanism by which 1-3 are taken up by cells. Glc-Pts 1–
3 are very hydrophilic (log P ~ –2) rendering cellular 
internalization via passive diffusion through the cellular lipid 
membrane highly unlikely. Furthermore, the lack of 
correlation between the log P values and cellular uptake is 
consistent with a protein-mediated transport mechanism 
(Figure S10a). The ovarian cancer cell line A2780 was 
chosen to evaluate the cellular uptake mechanism of the 
Glc-Pts because of its high level of GLUT1 expression,[17] 
confirmed by immunoblotting analyses (Figure S10b). 
Cellular uptake was first monitored in the absence and 
presence of an exofacial GLUT1 inhibitor 4,6-O-ethylidene-
α-D-glucose (EDG),[18] and the results are presented in 
Figures 2a and S14c. A 50% reduction in cellular uptake of 
1 was measured in the presence of 100 mM EDG. Under 
similar conditions, the reduction in the cellular uptake of 2 
and 3 was 38% and 30%, respectively. The cellular uptake 
of cisplatin did not change significantly in the presence of 
the inhibitor. Because cisplatin can be taken up via passive 
diffusion, this result matches well with our expectations. The 
inhibitor did, however, cause a 24% decrease in the cellular 
uptake of the aglycone 4. Because energy-dependent 
organic cation transporters (OCTs) contribute, at least in 
part, to the cellular uptake of 4 (Figure 2d, vide infra), we 
propose that the differential uptake induced by the presence 
of EDG most likely arises from the energy-depleted 
conditions produced by glucose transport inhibition. The 
extent of cellular uptake inhibition of the Glc-Pts in the 
presence of EDG is in the order 1>2>3 and this trend tracks 
with the cellular uptake of these compounds (Figure S5), 
providing further support for the proposal that the GLUT1 
translocation efficiencies for C6-glucose conjugates 
decrease with increasing linker length. Cumulatively, these 
results suggest that the cellular uptake of 1 is not only 
superior to, but is also more glucose-transporter-specific 
than, that of either 2 or 3. As a consequence, only 1 was 
used in the subsequent cellular uptake experiments. 
Similarly to co-treatment with EDG, a 50% reduction in 
the cellular uptake of 1 was observed when a structurally 
and functionally different glucose transport inhibitor, 
phloretin, was used (Figure S14b). Moreover, given that D-
glucose is the main substrate of GLUT1 and other glucose 
transporters, it should compete with and inhibit the protein-
mediated uptake of the Glc-Pts. When probed, D-glucose, 
but not L-glucose, exhibited a weak but statistically 
significant (p < 0.01) inhibitory effect on the uptake of 1 
(Figure 2b). The poor inhibitory effect (ca. 30% reduction in 
uptake) exerted by D-glucose can be attributed to the high 
binding affinity of 1 to glucose transporters, a phenomenon 
previously reported for other C6-glucose conjugates and 
GLUT1.[11b, 11c, 12] We also tested the effect of D-glucose on 
the cellular uptake of the aglycone 4 and found the uptake 
to be unaffected. Furthermore, in cytotoxicity assays carried 
out in the presence of EDG, the IC50 value of 1 increased 
19-fold (Figure 2c). We note that EDG does not affect the 
ability of 1 to platinate DNA in vitro (Figure S16). In contrast 
to the results with 1, only a 6-fold increase in IC50 value was 
observed during cotreatment with the control aglycone 4 
and EDG. The slight increase in IC50 value of 4 mirrors the 
observed decrease in cellular uptake of 4 in the presence 
of glucose transport inhibitors, which we attribute to energy 
depletion. In order probe Glc-Pt uptake through glucose 
transporters in an orthogonal manner, we capitalized on the 
fact that hypoxia causes stimulation of glucose transport 
and metabolism in cancer cells.[19] As shown in Figure 
S14a, cellular uptake of 1 increased by 50% when A549 
cells were treated with the hypoxia-inducing agent cobalt(II) 
chloride.[20] No significant difference in the uptake of 4 was 
observed under similar conditions. In summary, the uptake 
assays support the hypothesis that glucose transporters, 
such as GLUT1, are at least partially involved in the cellular 
entry mechanism of 1. 
 
Figure 2. (a) Effect of GLUT1 inhibitor EDG on the cellular uptake of 1–
4 and cisplatin (10 µM compounds, 17 h). (b) Effect of externally added 
D-glucose and L-glucose (10 µM compounds, 17 h). (c) Effect of EDG 
on the IC50 values (72 h assay). (d) Effect of EDG, Ctd, and their mixture 
on the cellular up-take of 1, 4 and oxaliplatin (10 µM compounds, 8 h). 
All experiments were done in A2780 cells and cellular uptake in absence 
of inhibitor was normalized to 100%. Data represent the mean ± SD of 
at least three or more replicates. The asterisks denote differences are 
statistically significant (*p < 0.01, **p < 0.001), ns = not statistically 
significant. 
It is well documented that organic cation transporter 2 
(OCT2) plays important roles in the cellular accumulation 
and consequent cytotoxicity of platinum complexes 
containing the (1R,2R)-cyclohexane-1,2-diamine (DACH) 
ligand.[21] OCT2- mediated cellular uptake has been 
suggested as a leading factor responsible for the sensitivity 
of colorectal cancer to oxaliplatin.[21] Because the Glc-Pts 
reported here bear the chelating DACH ligand, we 
investigated the potential of 1 to undergo translocation via 
OCT2, a transporter overexpressed in certain types of 
cancer cells and tumor samples from patients.[21-22] 
Expression of OCT2 in a panel of cancer cell lines was 
confirmed by Western blotting analysis (Figure S10b). 
A2780 cells were incubated with 10 µM 1 for 8 h in the 
presence or absence of EDG and/or the OCT2 inhibitor 
cimetidine (Ctd); oxaliplatin was employed as a positive 
control. In the presence of EDG, uptake of 1 was reduced 
by 50%, whereas the uptake levels of 4 and oxaliplatin were 
reduced by only 25% and 30%, respectively (Figure 2d). 
The OCT2 inhibitor Ctd reduces the uptake of the positive 
control compound oxaliplatin by 70%. Assays with Ctd 
revealed reductions of 45% and 35% in the cellular uptake 
of 1 and 4, respectively. These results support the 
involvement of OCT2 in the cellular internalization of both 1 
and 4. The uptake of 1 was further decreased by 20% (p < 
0.001) following treatment with a mixture of EDG and Ctd, 
compared to treatment with Ctd alone. These results further 
confirm the involvement of glucose transporters in the 
cellular uptake of 1 and indicate that OCT2 facilitates the 
cellular accumulation of 1 as well. 
An ideal anticancer compound should be selective for 
cancer cells over normal healthy cells, thereby mitigating 
undesired toxic side effects associated with chemotherapy. 
We therefore evaluated the selectivity of Glc-Pt 1 using 
DU145 prostate and A498 kidney cancer cells and matched 
normal prostate epithelial (RWPE2) and kidney epithelial 
(CCD1105 KIDTr) cells. Both of the cancerous cell lines 
have high levels of GLUT1 expression as compared to the 
normal epithelial cells (Figure S10b). Strikingly, as 
presented in Figure 3, the accumulation of 1 was 
significantly higher in the cancer cells as compared to the 
matched normal cells. Notably, the cellular uptake of 1 in 
DU145 cells is four-fold higher than RWPE2 cells, and it can 
be inhibited by the potent glucose transport inhibitor 
Cytochalasin B or the OCT2 inhibitor Ctd (Figure S15), 
suggesting that the cognate transporters mediate, at least 
in part, the preferential uptake of 1 by cancer cells. Similarly, 
1 reduced the viability of cancer cells more efficiently as 
compared to normal epithelial cells (Figure 3c and d).  
Given that neuronal cells express high levels of GLUT1 
transporters, adverse off-target neurological effects could 
arise with these glycoconjugates. We therefore evaluated 
the cytotoxicity of 1 in a murine hippocampal derived Neuro-
2A neuronal cell line, which is known to express the GLUT1 
transporter,[23] using short (8 h) and long (72 h) term assay. 
As shown in Figure S21, 1 has several fold higher IC50 
values in Neuro-2A cells (IC50 = 13.6±0.7 µM and 2.3±0.3 
µM at 8 h and 72 h, respectively) when compared to the 
most sensitive overian cancer A2780 cells (IC50 = 2.2±0.1 
µM and 0.15±0.06 µM for 8 h and 72 h assays, 
respectively). This result indicates that 1 is much more 
potent in ovarian cancer cells compared to neuronal Neuro-
2A cells in vitro. Encouragingly, neurotoxicity has not yet 
been observed in vivo for glycoconjugated drugs tested 
thus far.[7a] Moreover, no neurological adverse side effects 
were observed during a phase II clinical study of 
glufosamide, a glucose conjugated DNA alkylating agent 
ifosamide mustard.[24] 
Given that neuronal cells express high levels of GLUT1 
transporters, adverse off-target neurological effects could 
arise with these glycoconjugates. We therefore evaluated 
the cytotoxicity of 1 in a murine hippocampal derived Neuro-
2A neuronal cell line, which is known to express the GLUT1 
transporter,[23] using short (8 h) and long (72 h) term assay. 
As shown in Figure S21, 1 has several fold higher IC50 
values in Neuro-2A cells (IC50 = 13.6±0.7 µM and 2.3±0.3 
µM at 8 h and 72 h, respectively) when compared to the 
most sensitive overian cancer A2780 cells (IC50 = 2.2±0.1 
µM and 0.15±0.06 µM for 8 h and 72 h assays, 
respectively). This result indicates that 1 is much more 
potent in ovarian cancer cells compared to neuronal Neuro-
2A cells in vitro. Encouragingly, neurotoxicity has not yet 
been observed in vivo for glycoconjugated drugs tested 
thus far.[7a] Moreover, no neurological adverse side effects 
were observed during a phase II clinical study of 
glufosamide, a glucose conjugated DNA alkylating agent 
ifosamide mustard.[24] Finally, we note that the significant 
body of work showing preferential accumulation of 18FDG in 
tumors, used to diagnose malignancies, underscores the 
potential of glucose to become a powerful molecular tag for 
targeting cancer cells.[7d, 25] [7a] 
 
Figure 3. (a and b) Preferential accumulation of Glc-Pt 1 in prostate and 
kidney cancer cells as compared to matched normal epithelial cells (20 
µM, 8 h). (c and d) Effect of Glc-Pt 1 on the viability of cancer and 
matched normal cells. The asterisks denote differences that are 
statistically significant (*p<0.001, **p<0.02, ***p<0.01, ****p<0.002). 
In summary, novel C6-Glc-Pts were rationally designed 
and synthesized, and their mechanism of uptake was 
evaluated. Genomic DNA was confirmed to be one of the 
intracellular targets of the Glc-Pts. Among the Glc-Pts 
investigated, 1 most readily translocates through glucose 
transporters. The translocation efficiency and subsequent 
cellular accumulation were reduced with increasing size of 
the conjugate linker. Strikingly, 1 preferentially accumulates 
in and annihilates cancer cells while showing reduced 
accumulation and low toxicity in noncancerous cells in vitro. 
These results clearly demonstrate the potential of 
glycoconjugation for selective destruction of cancer cells by 
platinum compounds. To our knowledge, 1 represents the 
first glucose-platinum conjugate where a glucose-
transporter-mediated cellular uptake mechanism has been 
rigorously established. Furthermore, in addition to glucose 
transporters, OCT2 was identified as an additional 
transporter involved in the protein-mediated transport of 1, 
demonstrating the potential of 1 to exploit these two 
transporters, commonly overexpressed on the surface of 
tumor cells. 
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